[关键词]
[摘要]
目的 研究疏血通注射液联合羟苯磺酸钙胶囊治疗单纯型糖尿病视网膜病变的临床疗效。方法 选取2013年10月-2015年4月在秦皇岛市第一医院眼科诊治的单纯型糖尿病视网膜病变患者81例,随机分为对照组(40例)和治疗组(41例)。两组患者均给予常规治疗,控制血糖水平。对照组患者口服羟苯磺酸钙胶囊,0.5 g/次,3次/d。治疗组患者在对照组的基础上静脉滴注疏血通注射液,6.0 mL加入250 mL生理盐水中,1次/d。两组患者均连续治疗1个月。观察两组患者临床疗效,对比两组患者治疗前后的视力和血液流变学指标变化。结果 治疗后,对照组和治疗组临床总有效率分别为75.00%、95.12%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者视力比对照组患者明显好转,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血液流变学指标均较同组治疗前降低(P<0.05);且治疗组降低程度更显著,两组比较差异有统计学意义(P<0.05)。两组间不良反应发生比较差异无统计学意义。结论 疏血通注射液联合羟苯磺酸钙胶囊能够有效改善单纯型糖尿病视网膜病变患者的临床症状,降低血小板的聚集性和血浆黏度,并且不良反应发生率低,具有一定的临床应用推广价值。
[Key word]
[Abstract]
Objective To investigate clinical efficacy of Danshen Injection combined with Entecavir Tablets in treatment of chronic hepatitis B hepatic fibrosis. Methods The patients (136 cases) with chronic hepatitis B hepatic fibrosis in Xining No. 1 People's Hospital from October 2014 to October 2015 were randomly divided into control and treatment groups, and each group had 68 cases. The patients in the control group were po administered with Entecavir Tablets 0.5 mg, once daily. The patients in the treatment group were iv administered with Danshen Injection on the basis of the control group, 30 mL added into 5% Glucose Injection 250 mL, once daily. The patients in two groups were treated for 3 months. After treatment, the efficacy was evaluated, and indexes of liver fibrosis, serum levels of HBV-DNA and TGF-β1 in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 82.4% and 94.1%, respectively, and there were differences between two groups (P < 0.05). After treatment, HA, CIV, PIIINP, and LN in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, serum levels of HBV-DNA and TGF-β1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, serum levels of TGF-β1 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05), but there were no difference on serum levels of HBV-DNA between two groups. Conclusions Danshen Injection combined with Entecavir Tablets has clinical curative effect in treatment of chronic hepatitis B hepatic fibrosis, and can improve liver fibrosis, and also decrease the serum levels of TGF-β1, which has a certain clinical application value.
[中图分类号]
[基金项目]